Treatment of patients with immune-related adverse events after checkpoint inhibitors with extracorporeal photopheresis (ECP): a retrospective analysis and translational studies

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026642

Enrollment

Registered

2021-09-21

Start date

2021-09-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune-related adverse events (colitis, hepatitis, dermatitis, arthralgia) after treatment with immune checkpoint inhibitors (antibodies against PD-1, PD-L1 and CTLA4).

Interventions

Group 1: Analysis of leukocytes from patients who were treated with extracorporeal photopheresis for immune-related adverse events

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: age 18 years or older written informed consent previous Treatment with anti-PD-1, anti-PD-L1 or anti-CTLA4 antibodies development of irAE after treatment with immune checkpoint inhibitors treatment of irAE with ECP

Exclusion criteria

Exclusion criteria: previous treatment with ECP in the medical history

Design outcomes

Primary

Measure	Time frame
Expression of cell surface markers and cytokines on leukocytes from patients treated with extracorporeal photopheresis for immune-related adverse events after checkpoint inhibitor treatment. The analysis will be performed by flow cytometry on multiple time points between week 1 and 52 after beginning of ECP.	—

Secondary

Measure	Time frame
Correlations between immune phenotype and clinical outcome	—

Countries

Germany

Contacts

Public ContactPetya Apostolova

Klinik für Innere Medizin I

petya.apostolova@uniklinik-freiburg.de+4976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026